Article citationsMore>>

Minder, C.M., Blaha, M.J., Horne, A., Michos, E.D., Kaul, S. and Blumenthal, R.S. (2012) Evidence-Based Use of Statins for Primary Prevention of Cardiovascular Disease. American Journal of Medicine, 125, 440-446.
http://dx.doi.org/10.1016/j.amjmed.2011.11.013

has been cited by the following article:

• TITLE: The Impact of Statin Intolerance in Lipid Clinic Patients

  AUTHORS: Kate Williams, Vinita Mishra

  KEYWORDS: Statin Intolerance, Alternative Lipid Lowering Therapy, Low-Density Lipoprotein (LDL), Total Cholesterol

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.6 No.5, May 20, 2015

  ABSTRACT: Context: Cardiovascular disease is a very common and serious problem in the western world. Statin drug therapy is used in primary, secondary prevention and familial hypercholesterolemia. However, these are frequently associated with adverse effects, causing poor adherence and thus putting patients at risk for future cardiovascular events. Aim: The objective of this study was to review the statin intolerance in lipid patients and to assess the impact of alternative lipid lowering therapy on lipid parameters and cardiovascular outcome in statin intolerant patients. Methodology: 50 patients attending the out-patient lipid clinic of our hospital with statin intolerance were identified. Clinical data on the study patients were gathered retrospectively relating to statin intolerance and the clinical effectiveness of alternative lipid lowering therapy on lipid parameters and cardiovascular outcome. Results: Rosuvastatin was the most intolerable whereas pravastatin or fluvastatin was the most tolerable statin in our study patients. Myalgia was the commonly reported adverse effect of statin. The low dose statin monotherapy or combination of low dose statin and ezetemibe was the most tolerable alternative lipid lowering therapy in statin intolerant patients. After an average period of 10 months of initiation of alternative lipid lowering therapy; combination of low dose statin plus ezetimibe showed the largest reduction in serum total cholesterol and low-density lipoprotein (LDL) cholesterol levels. Conclusions: Pravastatin should be preferred in statin intolerant patients. A combination of low dose statin plus ezetimibe appeared to be the most tolerable and clinically effective therapy in statin intolerant patients.